Zimmer Biomet Q2 sales rise 4.8%, EPS up 33.8%, raises 2026 revenue and EPS guidance

Zimmer Biomet reported a 4.8% increase in second-quarter net sales to $2.177 billion and a 33.8% rise in diluted earnings per share to $1.03. The company generated $308.3 million in free cash flow and announced an increased share repurchase plan of up to $1 billion for 2026. It also received FDA clearance for its next-generation ROSA Shoulder System and raised its full-year 2026 revenue and adjusted EPS guidance, reflecting confidence in sustained growth driven by innovation and market expansion. Zimmer Biomet continues to focus on strategic priorities to strengthen its position as a leader in medical technology.